NASDAQ:SNDXSyndax Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Syndax Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.23 -0.61 (-3.85 %) (As of 08/10/2020 04:00 PM ET) Add Compare Share Today's Range$15.06Now: $15.23▼$15.7950-Day Range$13.39MA: $14.58▼$15.8452-Week Range$5.35Now: $15.23▼$21.97Volume415,209 shsAverage Volume533,842 shsMarket Capitalization$549.73 millionP/E RatioN/ADividend YieldN/ABeta1.76 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; with Tecentriq (atezolizumab) in a Phase Ib/II clinical trials to treat patients with triple-negative breast cancer, and HR+ and HER2- metastatic breast cancer; and with Bavencio (avelumab) in a Phase Ib/II clinical trials for the treatment of ovarian cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I dose escalation trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is in Phase I/Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; Merck KGaA and Pfizer; and AstraZeneca plc. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.38, Syndax Pharmaceuticals has a potential upside of 40.3% from its current price of $15.23.Amount of Analyst CoverageSyndax Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesSyndax Pharmaceuticals has received 315 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSyndax Pharmaceuticals has received 308 “underperform” votes. (Add your “underperform” vote.)Community SentimentSyndax Pharmaceuticals has received 50.56% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote “Outperform” if you believe SNDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Syndax Pharmaceuticals is held by insiders.Percentage Held by Institutions57.53% of the stock of Syndax Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($1.78) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -8.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -8.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 13.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.70 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNDX Previous Symbol CUSIPN/A CIK1395937 Webwww.syndax.com Phone781-419-1400Debt Debt-to-Equity Ratio0.38 Current Ratio5.55 Quick Ratio5.55Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.52 million Price / Sales361.66 Cash FlowN/A Price / Cash FlowN/A Book Value$1.16 per share Price / Book13.13Profitability EPS (Most Recent Fiscal Year)($1.84) Net Income$-56,050,000.00 Net Margins-4,155.11% Return on Equity-146.42% Return on Assets-77.16%Miscellaneous Employees38 Outstanding Shares36,095,000Market Cap$549.73 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $15.23 -0.61 (-3.85 %) (As of 08/10/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SNDX News and Ratings via Email Sign-up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions How has Syndax Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Syndax Pharmaceuticals' stock was trading at $11.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SNDX shares have increased by 29.2% and is now trading at $15.23. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Syndax Pharmaceuticals? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Syndax Pharmaceuticals. When is Syndax Pharmaceuticals' next earnings date? Syndax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Syndax Pharmaceuticals. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals Inc (NASDAQ:SNDX) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.42) EPS for the quarter, beating the Zacks' consensus estimate of ($0.47) by $0.05. Syndax Pharmaceuticals had a negative return on equity of 146.42% and a negative net margin of 4,155.11%. View Syndax Pharmaceuticals' earnings history. What price target have analysts set for SNDX? 9 equities research analysts have issued 12 month target prices for Syndax Pharmaceuticals' shares. Their forecasts range from $14.00 to $33.00. On average, they anticipate Syndax Pharmaceuticals' share price to reach $21.38 in the next twelve months. This suggests a possible upside of 40.3% from the stock's current price. View analysts' price targets for Syndax Pharmaceuticals. Has Syndax Pharmaceuticals been receiving favorable news coverage? News coverage about SNDX stock has trended somewhat negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Syndax Pharmaceuticals earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Syndax Pharmaceuticals. Who are some of Syndax Pharmaceuticals' key competitors? Some companies that are related to Syndax Pharmaceuticals include Karuna Therapeutics (KRTX), Apellis Pharmaceuticals (APLS), TG Therapeutics (TGTX), Turning Point Therapeutics (TPTX), Prestige Consumer Healthcare (PBH), Ligand Pharmaceuticals (LGND), Xencor (XNCR), Uniqure (QURE), Aurinia Pharmaceuticals (AUPH), Intercept Pharmaceuticals (ICPT), Seres Therapeutics (MCRB), I-Mab (IMAB), Revance Therapeutics (RVNC), Madrigal Pharmaceuticals (MDGL) and IGM Biosciences (IGMS). View all competitors. What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include Opko Health (OPK), Exelixis (EXEL), Verastem (VSTM), Micron Technology (MU), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), Clearside Biomedical (CLSD), Idera Pharmaceuticals (IDRA), Novavax (NVAX) and TG Therapeutics (TGTX). Who are Syndax Pharmaceuticals' key executives? Syndax Pharmaceuticals' management team includes the following people: Dr. Briggs W. Morrison M.D., CEO & Director (Age 59)Mr. Michael A. Metzger, Pres & COO (Age 48)Mr. Richard P. Shea, CFO & Treasurer (Age 67)Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 68)Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 50) When did Syndax Pharmaceuticals IPO? (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. What is Syndax Pharmaceuticals' stock symbol? Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX." Who are Syndax Pharmaceuticals' major shareholders? Syndax Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.96%), Assenagon Asset Management S.A. (0.49%), Russell Investments Group Ltd. (0.29%), UBS Group AG (0.08%), Sigma Planning Corp (0.07%) and New York State Common Retirement Fund (0.07%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison and Michael L Meyers. View institutional ownership trends for Syndax Pharmaceuticals. Which major investors are selling Syndax Pharmaceuticals stock? SNDX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. View insider buying and selling activity for Syndax Pharmaceuticals. Which major investors are buying Syndax Pharmaceuticals stock? SNDX stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Assenagon Asset Management S.A., Sigma Planning Corp, Virtus ETF Advisers LLC, Trexquant Investment LP, SG Americas Securities LLC, UBS Group AG, and New York State Common Retirement Fund. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison, and Michael L Meyers. View insider buying and selling activity for Syndax Pharmaceuticals. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Syndax Pharmaceuticals' stock price today? One share of SNDX stock can currently be purchased for approximately $15.23. How big of a company is Syndax Pharmaceuticals? Syndax Pharmaceuticals has a market capitalization of $549.73 million and generates $1.52 million in revenue each year. The company earns $-56,050,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Syndax Pharmaceuticals employs 38 workers across the globe. What is Syndax Pharmaceuticals' official website? The official website for Syndax Pharmaceuticals is www.syndax.com. How can I contact Syndax Pharmaceuticals? Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected] This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
